The problem addressed by the present invention is to provide a novel medicinal agent for the prevention and/or treatment of a viral infection. The present invention provides a medicinal agent for the prevention and/or treatment of a viral infection other than hepatitis C, and contains as the active ingredient the compound represented by general formula (I) or a salt thereof [In the formula, X represents a nitrogen atom or C‑R4 R1, R2, R3, and R4 each independently represent a hydrogen atom, C1‑6 alkyl group, C2‑6 alkenyl group, C2‑6 alkynyl group, C1‑6 alkoxy group, halogen atom, nitro group, amino group, C1‑3 mono- or di-alkyl amino group, C1‑3 alkyl carbonylamino group optionally substituted by a phenyl group, benzoyl amino group, trifluoromethyl group, azido group, carboxyl group, C1‑3 alkyl carbonyl group, C1‑3 alkoxy carbonyl group, carbamoyl group, naphthyl group, optionally substituted heteroaryl group, styryl group, C1‑3 alkyl thio group, C1‑6 hydroxyalkyl group, or a group having the structure represented by general formula (1) in the description R2 and R3, or R3 and R4 are optionally crosslinked R5 represents an optionally substituted C1‑5 straight chain alkylene group, with substituents on the alkylene group optionally bonded together to form a ring structure].Lobjectif de cette invention est de pourvoir à un nouvel agent thérapeutique pour prévenir et/ou traiter linfection virale. Pour ce faire, lagent thérapeutique selon linvention pour prévenir et/ou traiter une infection virale autre que lhépatite C contient, à titre de principe actif, le composé représenté par la formule générale (I) ou un sel de celui-ci. [Dans la formule, X représente un atome dazote ou C‑R4 R1, R2, R3, et R4 représentent chacun indépendamment un atome dhydrogène, un groupe alkyle C1‑6, un groupe alcényle C2‑6, un groupe alcynyle C2‑6, un groupe alcoxy C1‑6, un atome dhalogène, un groupe nitro, un groupe amino, un groupe mono- ou dialkyl(C1‑3)amino, un groupe alkyl(C1‑3)carbonylam
